...
首页> 外文期刊>Renal replacement therapy. >Association between serum ferritin levels and clinical outcomes in maintenance hemodialysis patients: a retrospective single-center cohort study
【24h】

Association between serum ferritin levels and clinical outcomes in maintenance hemodialysis patients: a retrospective single-center cohort study

机译:血清铁蛋白水平与维持血液透析患者临床结果的关系:回顾性单中心队列研究

获取原文
           

摘要

Ferritin is a well-known marker of iron deficiency anemia, but the target in maintenance hemodialysis (MHD) patients remains controversial. This study examined the association between baseline ferritin levels and clinical outcomes. We retrospectively collected the data of outpatients on MHD for 5?years at St. Luke’s International Hospital from July 2009. Patients with baseline ferritin levels of ?100?ng/mL in June 2009 were defined as the high-ferritin (HF) group and the remaining patients as the low-ferritin (LF) group. The primary endpoint was all-cause mortality. The secondary endpoints included cardiovascular events and infection-related hospitalizations. Log-rank test and Cox proportional hazard analysis were performed. Of 116 patients (age, 65.4?±?13.4?years, 70% males), 29 (25%) and 87 (75%) belonged to the HF and LF groups, respectively. During the follow-up period of 1825 (interquartile range 819–1825) days, 38 patients (23 in the HF and 15 in the LF groups) died. According to the Kaplan–Meier survival curves, the HF group had significantly poor survival compared with the LF group (p?=?0.0089). After adjusting for age, sex, vintage of hemodialysis, C-reactive protein levels, and history of cardiovascular events, the hazard ratio (HR) for the HF group was 2.49 (95% confidence interval (CI), 1.21–5.12). The multivariate analysis of cardiovascular events revealed a similar result with statistical significance (HR 2.69; 95% CI 1.12–6.46). Infection-related hospitalizations did not exhibit any statistically significant difference. In MHD patients, ferritin levels ?100?ng/mL is associated with increased rates of all-cause mortality and cardiovascular events.
机译:铁蛋白是一种众所周知的缺铁性贫血标记,但维持血液透析(MHD)患者的靶标仍然存在争议。本研究检测了基线铁蛋白水平与临床结果之间的关联。我们回顾了2009年7月在圣卢克国际医院的5岁时收集了MHD的门诊病人的数据。2009年6月的基线铁蛋白水平>?100?NG / ML的患者被定义为高铁蛋白(HF)组和剩下的患者作为低铁蛋白(LF)组。主要终点是全部导致死亡率。次要终点包括心血管事件和相关的感染住院治疗。进行日志秩测试和COX比例危险分析。 116名患者(年龄,65.4〜±13.4岁,70%雄性),29(25%)和87(75%)分别属于HF和LF组。在1825年的后续期间(第819-18252525252525252525252525252525252525252525年的间隔范围)日,38例患者(62例,LF组中的23个)死亡。根据Kaplan-Meier存活曲线,与LF组相比,HF组的存活显着差(P?= 0.0089)。调整年龄,性别,血液透析复古,C反应蛋白水平和心血管事件的历史,HF组的危险比(HR)为2.49(95%置信区间(CI),1.21-5.12)。心血管事件的多变量分析显示出类似的统计学结果(HR 2.69; 95%CI 1.12-6.46)。有关相关住院治疗没有表现出任何统计学意义的差异。在MHD患者中,铁蛋白水平>?100?Ng / ml与全导致死亡率和心血管事件的提高相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号